Jefferies Cuts Price Target on Immune Design (IMDZ) to $15 Following 3Q
Jefferies maintained a Buy rating on Immune Design (NASDAQ: IMDZ), and cut the price target to $15.00 (from $17.00), following ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)